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1.1 Overview and incidence  
Spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by degeneration of 
alpha motor neurons resulting in hypotonia, progressive muscular weakness and atrophy.30 
Spinal muscular atrophy is one of the leading hereditary causes of infant mortality,31 it 
comprises the second most common fatal progressive diseases after cystic fibrosis.28 Spinal 
muscular atrophy is the most common neuromuscular disease in childhood after Duchenne 
muscular dystrophy with an estimated incidence of 1 per 5,000 to 10,000 live births.4,11  
2. Pathogenesis  
Spinal muscular atrophy is known to be genetic disorder that is inherited as an autosomal 
recessive disorder but some dominant or X-linked traits are reported. The pathological basis 
of SMA is abnormality of the large anterior horn cells in the spinal cord caused by deletion 
or mutation of the Survival Motor Neuron-1 (SMN1) gene located at chromosome region 
5q.1 Absence of all or part of the SMN has been detected in 98% of patients with SMA18 and 
results in reduction of the full length protein necessary for proper function of the anterior 
horn cells.10,13 The decreased level of the SMN protein results in selective death of spinal 
motor neurons,31 with the severity of the disease being inversely proportional to the amount 
of the SMN in the anterior horn cells.1The severity of SMA ranges from total paralysis and 
need for ventilatory support to relatively mild muscle weakness.1, 32 
3. Clinical manifestation and classification  
SMA is manifested by various clinical features that cause a variety of debilitating symptoms. 
Muscle weakness is a hallmark feature of SMA and patients with SMA are among the 
weakest and most hypotonic seen in any muscle clinic.13 Clinically, the disease is 
characterized by progressive symmetrical muscle weakness, which starts proximally and 
moves distally, with the proximal muscles being more affected than the distal muscles.5 
Muscle weakness is associated with muscle atrophy, hypotonia, absence or marked decrease 
of deep tendon reflexes, fasciculation of the tongue, and tremors of the hand.5,20 Patients 
with SMA have normal intellectual function. Contractures and spinal deformity have been 
reported to be common impairments. Pulmonary infections and restrictive lung disease are 
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the most serious complications in SMA.12 In general, the clinical course of SMA is highly 
variable, and it is more of a continuous spectrum with the age of onset from birth to 
adulthood, and the age of death from infancy to normal life expectancy. The severity of the 
diseases and clinical manifestations show a continuous range from the very severe to very 
mild forms of the disease.20 With age, muscle weakness increases, and the symptoms 
progress and patients lose their functions over time.25 The progression of the disease process 
varies both between and within types.21 Current evidence suggests that maximum function 
achieved is more closely related to life expectancy than age at onset.24 Based on the age at 
onset, clinical presentation, and the maximum functional level achieved, SMA is usually 
classified into the following broad types.  
3.1 Type I SMA (Werdnig-Hoffmann disease) 
Type I SMA is the most severe form of SMA, it is also known as Werdnig-Hoffman disease. 
The age of onset is typically from birth or in the first 6 months of life and the child never 
developing independent sitting. Werdnig-Hoffmann disease is characterized by severe 
generalized muscle weakness and hypotonia.20 Infants typically have significant wasting, 
and weakness in the limbs and trunk and present with decreased movements, especially 
against gravity. Most infants present with lack of head control and are never able to roll 
from supine or to pull to sitting.13 Significant oral motor weakness results in difficulties in 
sucking and swallowing and makes feeding progressively more difficult. Weakness of the 
intercostal muscles results in limited respiratory function, and breathing is usually entirely 
diaphragmatic resulting in development of abnormal breathing patterns and respiratory 
complications. The severity of respiratory complications is generally proportional to the 
weakness.24 Early morbidity and mortality are commonly associated with pulmonary 
complications,30 and death occurs during the first 2 to 3 years of life.  
3.2 Type II SMA (Intermediate form) 
Children with the intermediate form have an onset between 6 and 18 months of age.17 They 
are able to sit and may develop ability to stand but they are unable to walk 
independently.21,30 Some of the less involved children are able to walk with braces or 
assistive devices at some point of their life.8 Children with type II exhibit symptoms of 
weakness similar to type I SMA but with much less severe degree. Distal muscle weakness is 
less severe than proximal muscle weakness and starts later in the course of the disease.  There 
is a delay in the acquisition of motor skills, with the majority of those children sit at the age of 
12 months of age. As the disease progresses, children exhibit more weakness and regressed 
gross motor development. Feeding and swallowing are not difficult. Contractures are common 
including scoliosis or kyphoscoliosis. Early onset and rapidly progressing scoliosis is 
uniformly present; severity of scoliosis increases as the disease progresses and may require 
bracing and/or spinal fusion. Pulmonary complications are pervasive especially with scoliosis 
and as the disease progresses. Ventilatory assistance is common in later stages of the disease.    
3.3 Type III SMA (Kugelberg-Welander disease) 
Type III SMA, often referred to as Kugelberg-Welander disease or Juvenile-onset SMA, is 
the mild form of the disease. Children with type III SMA have an onset age typically after 18 
months. This form is more variable in age of onset, although most diagnosis prior to age 3 
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years is typical, weakness in other mild cases may not be noticeable until late childhood. 
Patients are able to achieve independent walking and whilst some children may lose this 
ability in childhood, others maintain walking until adolescence or adulthood.30 Early motor 
milestones are often normal, including ability to walk, which is achieved at the normal age 
or slightly late. Although they are able to ambulate, they may show difficulty with walking 
at some point in their clinical course secondary to proximal muscle weakness. Walking is 
characterized by lack of balance, falls, increased lumbar lordosis, hyperextended knees or 
genu recurvatum, and excessive waddling. Muscle weakness mainly affects proximal 
muscles of the lower extremities and is less severe than types I and II SMA. Proximal muscle 
weakness often results in difficulty in stairs climbing, hopping, running and jumping. 
Gower’s’ maneuver may be present when getting up off the floor. Scoliosis and pulmonary 
complications are common in patients with type III SMA but less frequent and not severe as 
in patients with type II SMA. The incidence and severity of complications including scoliosis 
and pulmonary complications are related to the degree of muscle weakness and the 
functional status. Many patients with type III lose the ability to functionally ambulate as 
they get weaker during adulthood. Individuals with type III SMA usually have normal life 
expectancy.  
3.4 SMA type IV (Adult-onset form) 
Adult-onset SMA is a rare type. The onset of the disease is in the adulthood, typically in the 
third or fourth decades. The signs and symptoms are similar to those of type III SMA but the 
impairments and degree of disability are often mild. Life expectancy is normal.  
3.5 Other forms of SMA 
There are other very rare types of SMA disorders with similar symptoms but they are 
caused by different genes other than SMN1 and genetic mutation. Other forms of SMA 
include distal spinal muscular atrophy, characterized by distal muscle weakness; X-linked 
spinal and bulbar muscular atrophy (Kennedy disease), an X-linked adult onset form of SMA; 
childhood bulbar SMA (Fazio-londe disease), a progressive bulbar palsy; Hexosaminidase a 
deficiency, with variable neurologic findings, including progressive dystonia, spinocerebellar 
degeneration, and lower motor neuron disease; and Monomelic muscular atrophy, a cervical 
form of spinal muscular atrophy.24 
4. Diagnosis  
Diagnosis of SMA is suspected on the bases of the clinical picture, muscle biopsy and 
electromyography. Genetic testing is the only definitive diagnostic test for patients with 
SMA. With the use of genetic testing, the role of EMG and muscle biopsy in confirming the 
diagnosis of SMA is limited. They can be used for the diagnosis of patients with SMA who 
present without homozygous deletion of the SMN gene.32 Genetic testing of SMA shows a 
deletion of the SMN gene on the fifth chromosome. EMG findings usually show a pattern of 
denervation including fibrillation potentials, positive sharp waves, and large amplitude, 
short duration actions potentials. Sensory nerve conduction velocities are normal with no 
marked decrease of motor nerve conduction velocities. Muscle biopsy provides evidence of 
muscle denervation with groups of small atrophic fibers with large hypertrophic fibers. 
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5. Prognosis 
The course of SMA is relentlessly progressive. Prognosis varies according to the age of 
onset, type of SMA, and the maximum function achieved. The age at the time of the onset 
has the strongest relationship to prognosis. It appears that the earlier the onset of the 
disease, the faster the progression and the poorer the prognosis. The current prognosis for 
children with type I SMA is very poor, with the death usually occurs in the first two years of 
life as a result of respiratory failure caused by respiratory complications.  Some children 
with SMA type I can survive beyond two years of age with the use of ventilator assistance.1 
The prognosis of type II SMA is extremely variable. Patients with type II SMA have short 
life span; survival into adulthood is possible with aggressive respiratory care. Majority of 
patients with type III SMA remain independent in ambulation throughout adult life. 
Patients with Type III SMA are expected to have normal life expectancy. Patients with the 
onset begins before two years of age continue to ambulate until an average of twelve years 
of age. Patients with the onset after two years of age continue to ambulate throughout the 
adult life.25 
6. Assessment 
Since assessment is important for guiding clinical management and for evaluating 
therapeutic outcomes, thorough assessment of patients with SMA is essential. Assessment 
should include regular assessment pertinent to children with neuromuscular disorders 
such as assessment of posture, muscle strength, performance, range of motion, gait 
assessment, respiratory assessment, and quality of life measures. Assessment of functional 
status and level of disability using standardized outcome measures should be also 
included.  
6.1 Joint integrity, range of motion and muscle flexibility 
Active and passive joint range of motion can be assessed using goniometry. Functional 
range of motion, muscle length, and soft tissue flexibility should be assessed using standard 
methods. Assessment of joint integrity, range of motion and muscle flexibility should be 
done periodically to monitor development of contractures, particularly when the patient 
loses ability to ambulate.  
6.2 Assessment of posture 
Routine posture examination should be performed on a regular basis. Posture examination 
includes examination of resting posture and changes in posture that occur with movement. 
Examination for the presence of scoliosis is essential especially for patients who are 
wheelchair dependent. 
6.3 Muscle strength 
Assessing muscle strength in children can be difficult, because the results depend on the 
patient’s effort.15 Strength deficits in children with SMA can be assessed using manual 
muscle testing (MMT) or hand-held dynamometer. Manual muscle testing is the most 
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widely method to assess muscle strength in clinical practice. It is a reasonably easy and 
inexpensive in measuring muscle strength in patients with SMA, but it does not allow 
grading small changes in muscle strength. A handheld dynamometer can be used to 
quantify muscle strength. Using a dynamometer is easy and comfortable and allows for 
measuring small changes in strength over a continuous range.19 
6.4 Respiratory function 
Pulmonary function tests are parts of the regular assessment in patients with SMA to 
monitor changes in respiratory status. Routine assessment of respiratory function includes 
complete pulmonary function tests, including sprirometery, lung volumes, and respiratory 
muscle function tests.30 Assessments of cough effectiveness and breathing pattern are 
important for the non-ambulatory patients or patients who are too weak or too young to 
perform pulmonary function testing.30  
6.5 Gait 
No disease-specific gait test or measure exists for patients with SMA. Description of gait 
deviations and safety and stability during walking should be included as part of routine gait 
analysis. The 10-Meter Walk test can be used to measure gait speed. The Six Minute Walk 
Test or the Two Minute Walk Test can be used to measure endurance during gait.  
6.6 Measurement of functional status and quality of life  
Examination of functional status including examination of functional mobility skills and 
activities of daily living is an important consideration. Several clinical outcome measures 
can be used to measure functional outcomes in patients with SMA including generic 
measures and disease-specific measures. Generic outcome measures commonly used in 
patients with SMA include the Gross Motor Function Measure, the Test of Infant Motor 
Performance, the Alberta Infant Motor Scale, the Wee Functional Independence Measure, 
the Motor Function Measure, and the EgenKlassifikation Scale. Disease-specific outcome 
measures include the Hammersmith Functional Motor Scale, the Modified Hammersmith 
Functional Motor Scale, the Expanded Hammersmith Functional Motor Scale, the Children’s 
Hospital of Philadelphia Test of Strength in spinal muscular atrophy, the Infant Test for 
Neuromuscular Disease, and the Spinal Muscular Atrophy Functional Rating Scale. Selection 
of the outcome measures to be used is based on age of the patient, patient’s functional level, 
aspects of function being measured, ease of administration, and burden imposed on the 
patient. The Pediatric Quality of Life Inventory (PedsQL) instrument can be used to measure 
quality of life.  
7. Management  
No specific therapy is currently available for SMA. Treatment is usually supportive, and 
may include physical therapy, occupational therapy, nutrition, orthotic management, and 
possibly surgical intervention. Appropriate recommendations are made on the basis of each 
patient’s presentation and functional level.15 The most important goal in the management of 
the patients is to achieve maximal independent living with maximized mobility, and to 
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prevent the development of complications.2,9,13,15,30 Treatment focuses on prevention of 
complications of severe weakness including restrictive lung disease, orthopedic deformities, 
immobility, and psychosocial problems. 
The multidisciplinary approach is important to assess and address the needs of the 
patient/family. The multidisciplinary team might consist of neurologist, pediatrician, 
physiatrist, physical therapist, occupational therapist, speech therapist, nutritionist, 
pulmonary specialist, orthotist, genetic counselor, social worker, and psychologist. Family 
education and patient/family centered care are important parts in the management of 
patients with SMA. Education should include the disease process, associated impairments 
and complications, physical limitations, functional abilities, prognosis, and expected 
outcomes.  
7.1 Therapeutic exercises and strength training 
The overall therapeutic goals are to achieve maximal independence in mobility,15 and to 
prevent and delay progression of complications. Exercise programs may help to improve 
and maintain range of motion, maintain mobility, and prevent or slow the progression of 
contractures, orthopedic deformities and respiratory failure. 
Strengthening exercises have been shown to be effective to slow the deterioration of muscle 
weakness in patients with neuromuscular disorders. Strengthening exercises may prolong 
ambulation and delay dependence on wheelchair for mobility in patients with 
neuromuscular disorders including children with Duchenne muscular dystrophy. 
Strengthening exercises may be used to slow the deterioration in muscle strength. The role 
of strengthening exercises in SMA is not well established due to lack of clinical trials on the 
effects of exercise programs and lack of trials critical data to support appropriate exercise 
prescription. Appropriate exercise recommendations in SMA are based on the patient’s 
presentations and functional status, and therapists’ experience with similar neuromuscular 
conditions. Recommendations regarding strengthening of patients with SMA include 
precautions and guidelines from other degenerative muscle diseases.7  
In patients with neuromuscular diseases, excessive strengthening exercises may contribute to 
deterioration in muscle strength by increasing muscle degeneration.7 Therefore, excessively 
strenuous strengthening such as excessive resistive exercises, eccentric exercises, and maximal 
aerobic training should be avoided. Excessive fatigue and overwork weakness should be 
avoided, frequent rests and self-initiated rests should be given frequently especially for the 
weaker patients and patients with decreased respiratory functions. Positioning and support 
can be used to maximize biomechanical advantage and minimize the effects of gravity. 
Monitoring with oximetry is recommended particularly for patients with compromised 
respiratory functions. It is important to monitor responses to exercises such as fatigue, pain, 
and muscle soreness.   
Strengthening exercises for SMA may include low-intensity strengthening exercises, and 
submaximal aerobic exercise. Since there is no evidence to support traditional strength 
training for patients with SMA, practicing functional activities and tasks of activities of daily 
living may be good recommendation for those individuals. These exercises and activities 
should be designed based on the age, developmental stage, and functional level.  
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Exercise strategies for young children and infants may include practicing developmental 
skills. This includes activities to facilitate head and trunk control; floor mobility skills such 
as rolling and creeping; facilitation of weight shift and weight bearing and transitions 
between positions; and facilitations of upright positions and skills such as sitting, standing 
and walking as appropriate.3 For the less involved and older individuals, exercise strategies 
include practice functional activities such as standing and walking, and gentle aerobic 
programs.  
7.2 Participation in physical activities 
Weakness and difficulty in moving independently in patients with SMA contribute to 
physical inactivity and limited participation in exercise programs. The consequences of 
physical inactivity are particularly detrimental, could contribute to secondary impairments 
and may lead to additional decline in functional status. Recent evidence suggests that 
engagement in physical activities helps improve physical functioning in children with 
disability. Participation in physical activities may promote physical functioning, quality of 
life, health, and well-being.  
Participation in physical activity may include participation in recreational and sports 
activities. Recreational programs that can be beneficial include swimming, cycling, and 
riding when appropriate.6 Activities should be selected carefully with the goal of improving 
functional performance and daily activities, promoting aerobic fitness and preventing 
complications of inactivity. Activities should be selected based on the age, developmental 
skills, and functional abilities.  
7.3 Aquatic exercises 
Aquatic therapy or hydrotherapy is being used on an increasing basis and has been shown 
to be beneficial for children with SMA.26 The use of aquatic therapy in SMA may be related 
to the physical properties of water. The properties of water provide weight relief and 
postural support, facilitate antigravity movements allowing more freedom of movement, 
and provide an opportunity to perform activities that may be too difficult to accomplish on 
land.26 Aquatic exercises provide low-intensity strength training, walking and balance 
exercises, and aerobic training without the fear of fatigue or overwork.  
7.4 Feeding and nutrition 
Infants with type I SMA have poor oral motor control with sucking and chewing and 
tendency to get fatigued easily during feeding and swallowing. Lack of head control and 
head support may also affect swallowing. Those children may have difficulty getting 
enough nutrition and are at risk of aspiration. Some infants may require indwelling 
nasogastric tube to supplement oral feeding. Gastrostomy may be an option for some 
children to improve carer satisfaction and quality of life,23 and to avoid aspiration.  
7.5 Management of contractures 
Muscle contractures and orthopedic deformities are common complications among patients 
with SMA. Contractures and orthopedic deformities occur primarily in type II and type III 
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patients who have longer periods of muscle weakness.  Contractures develop secondary to 
muscle weakness, muscle imbalance, lack of mobility, and poor posture and positioning. 
Development and severity of contractures are related to the severity of muscle weakness, 
the duration of muscle weakness, and immobility. Muscle contractures are common in 
muscles that cross two joints or more. Classic contractures are seen in iliotibial band, hip 
flexors, knee flexors and plantar flexors. 
Prevention and treatment of contractures are important issues in the management of 
patients with SMA. Management of contractures should begin before the contractures exist. 
Management of contractures includes combination of consistent program of range of motion 
exercises, positioning, regular stretching, and splinting. Muscle groups that are at risk of 
developing contractures should be targeted for stretching. Range of motion and stretching 
exercises can be used to preserve and increase flexibility. Active range of motion and 
stretching exercises can be used to maintain flexibility and prevent contractures in the 
ambulatory patients. In the non-ambulatory patients, regular range of motion program and 
passive stretching are used to prevent development and slow progression of contractures. 
Ankle foot orthoses and night splints can be used to maintain flexibility and range of 
motion. Positioning devices and custom fitted equipment can be used for positioning to 
provide low-intensity prolonged stretching. A tilt in space or recliner chairs can be used to 
allow easy positioning changes. Standing program provides low-intensity prolonged stretch 
that can be used for the non-ambulatory children.    
7.6 Adaptive equipment and assistive devices  
Patients with SMA frequently benefit from use of assistive and adaptive devices, with 
changing needs as their condition progresses. Adaptive equipment and assistive devices can 
be used to provide positioning, control contractures and deformities, and support function. 
The choice of assistive devices for patients with SMA is based on individual clinical 
decisions due to lack of definite intervention trials. The decision to use an assistive device 
should be a collaborative decision between the patient, family, orthopedic surgeon, 
physiatrist, and therapist.  
7.6.1 Orthotics 
Ankle foot orthoses (AFO) or night splint can be used to provide prolonged stretch to 
control the progression of plantar flexion contractures. Knee splints may be used to control 
hamstring flexibility and knee flexion contractures. Thigh binders can be used to control 
iliotibial band contractures. Assistive devices including braces, taping, AFO, knee-ankle-foot 
orthoses (KAFO), and hip-knee-ankle-foot orthoses (HKAFO) can be used to provide 
support and maintain joints alignments. Assistive devices may be used to facilitate stability, 
weight bearing and upright posture during standing and ambulation.  
7.6.2 Positioning devices 
Positioning devices can be used to provide support, and control contractures and 
deformities. Positioning devices can be custom fitted, special foam, or cushions. They allow 
easy positioning and stretching, and provide support. Head and trunk lateral support can be 
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used to accommodate for weak neck and trunk muscles and lack of head and trunk control, 
they can be used to assist in positioning and to maintain upright head and trunk during 
sitting.  
7.6.3 Standing devices 
Non-ambulatory patients with SMA may benefit from a standing program using standing 
frames or swivel walkers. Standing programs are used for non-ambulatory patients to 
prevent or reduce secondary impairments by maintaining muscle extensibility, preventing 
muscle and soft tissue contracture, promoting optimal musculoskeletal development, and to 
address the issue of reduced bone mineral density.27,29 
7.6.4 Wheelchairs and seating systems  
Because of the progressive weakness associated with SMA, many patients benefit from a 
wheeled mobility device as the primary means of locomotion. Wheelchair seating system 
deserves special considerations since many patients require a full-time use of the wheeled 
mobility device. The course and progression of the disease, presenting symptoms, degree of 
spinal deformity, and whether the patient is using mechanical ventilation should be taken 
into considerations when deciding on a mobility device. Manual wheelchairs allow the 
patients to maintain upper body strength and cardiovascular endurance. A power wheelchair 
should be considered when impairments prevent manual propulsion. Power wheelchairs 
enable patients to maintain a level of independence while moving within their environment 
and to compensate for mobility limitations.14 For young children who are not ambulatory, 
power mobility may be used to provide independent mobility at appropriate developmental 
age.25 Children as young as two years can independently propel wheelchair.14, 25 
7.7 Management of scoliosis  
Progressive weakness and reduced mobility associated with SMA place the patients at risk 
of contractures and scoliosis. Scoliosis is the most serious orthopedic problem seen in 
patients with SMA. Scoliosis develops earlier and progresses faster in non-ambulatory 
children than ambulatory children, scoliosis is seen in almost all children with type II SMA 
and majority of patients with type III, with the severity is less in type III SMA as compared 
to type II SMA. The incidence and severity of scoliosis increase with age and severity of 
muscle weakness, with the severity and progression of scoliosis increase once patients lose 
ambulation and become dependent on wheelchair for ambulation. Reduced respiratory 
function is common in patients with scoliosis. As muscle weakness progresses, the degree of 
scoliosis increases causing more discomfort and difficulty in positioning and respiration. 
Presence and degree of spinal deformity should be monitored periodically by examination 
and routine radiography, particularly for the non-ambulatory patients or as patient loses 
ambulation. Spinal x-rays are indicated once there is clinically detected scoliosis.32 Range of 
motion program and spinal positioning are important to provide comfort and slow the 
progression of spinal deformities. Adequate trunk supports on a wheelchair, and wheelchair 
modifications such as custom molding, gel or air cushions may be needed to provide 
maximum support, and comfort and may minimize the progression of spinal deformity. As 
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scoliosis progresses, external bracing such as thoraco-lumbo-sacral orthosis can be used to 
provide support and to apply forces to realign the vertebral column. External bracing is 
used to reduce, prevent, or slow the progression of scoliosis.16 Surgical correction of scoliosis 
is required for patients to stop the progression of scoliosis and to maintain function and 
respiratory reserve.22 The decision and timing of surgical intervention are based on degree 
of scoliosis, curve progression, pulmonary function, and bony maturity.30 Surgical 
correction of spinal fusion is indicated to prevent further progression and deterioration of 
scoliosis and respiratory function. The outcomes of spinal stabilization include improved 
sitting balance, endurance and cosmetics30 and slowed pulmonary progression. Intensive 
preoperative and postoperative physical therapy is required to prevent respiratory 
complications, and loss of strength or function after spinal fusion.13 Orthotic intervention, 
new wheelchair or wheelchair modification are likely to be required after the surgeries and 
should be included in the preoperative plan of care.  
7.8 Management of respiratory complications  
Lung diseases resulting from weakness associated with SMA are the most common and 
most serious complications of SMA.12 Respiratory impairments place the patient at risk for 
respiratory tract infections, and pulmonary insufficiency/failure, and are the major causes 
of morbidity and mortality. 
The key respiratory problems in SMA are impaired cough with poor clearance of lower 
airway secretions; hypoventilation; chest wall and lung underdevelopment; and recurrent 
infections.30  Sleep-disordered breathing resulting from hypoventilation is common in SMA. 
Cardiopulmonary endurance reduces markedly once the child becomes wheelchair 
dependent. Increased weakness, decreased mobility level, and development of scoliosis are 
important factors to consider when assessing the respiratory function and progression of 
respiratory complications.  
Patients with SMA should be evaluated by a respiratory care specialist. Routine evaluation 
of respiratory function including pulmonary function testing should be done on a regular 
bases. Pulmonary function testing with forced vital capacity can be used as a baseline and as 
a predictor of respiratory reserve. Pulse oximeters can be used at home as to indicate when 
the child is not ventilating properly.12 
Providing information about respiratory care and anticipated future needs is crucial to 
respiratory management of SMA.30 Patients with SMA and their families should learn how 
to monitor the respiratory function. Signs of respiratory insufficiency include deceased 
alertness, confusion, headache, pallor, and night-time restlessness.   
Chest infections should be treated with antibiotics, postural drainage, chest physical 
therapy, and when appropriate, assisted ventilation. Patients and families should be 
educated on how to perform postural drainage techniques, assisted coughing, and breathing 
exercises.  
Respiratory care for patients with SMA includes airway clearance techniques, respiratory 
exercises, chest physical therapy, and noninvasive ventilation, including intermittent 
positive pressure ventilation, bilevel positive airway pressure ventilation, and negative 
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pressure ventilation. Ventilatory assistance might be used for patients with respiratory 
failure.  
7.9 Genetic counseling  
Genetic counseling for patients or parents who wish to have another child is extremely 
important. SMA genetic testing can be used for carrier detection and detection of an affected 
fetus.  
7.10 Vocational counseling 
Some patients with SMA are limited to occupations that do not require physical demands. 
Vocational counseling and planning may be beneficial early during high school years to 
facilitate transition from school to postsecondary education. Vocational counseling may be 
necessary to help adjustment to work settings.  
7.11 Psychological support 
Counseling and psychological support are important strategies in the management of SMA. 
Anxiety and depression can greatly impact patients and families’ quality of life and their 
abilities to cope with the diseases and progressive changes in function and abilities. Formal 
counseling and psychological support should be available to assist patients and families 
coping with the severity and progression of the disease. Patients and families should be 
educated regarding the disease process and expectations and making sure that families are 
having the appropriate expectations for mobility and function.  
8. Summary 
Spinal muscular atrophy, a neuromuscular disorder, is one of the leading genetic causes of 
infant mortality. The disease is caused by deletion or mutation of the SMN1 gene and a 
reduction in the levels of functional SMN, resulting in selective death of spinal motor 
neurons. The type of SMA (I, II, III, or IV) is determined by the age of onset, the severity of 
symptoms, and the maximum function achieved. There are other rare types of SMA 
disorders with similar symptoms but they are caused by different genes other than SMN1 
and genetic mutation. Spinal muscular atrophy is characterized by severe progressive 
muscle weakness, atrophy and hypotonia. Complications of muscle weakness include 
decreased mobility function, restrictive lung disease, contractures, orthopedic deformities 
and psychosocial problems. There is no cure for SMA. Treatment is usually supportive and 
focuses on management of the symptoms and preventing complications of muscle 
weakness. Pulmonary complication is a hallmark of the disease and is the main cause of 
death especially in type I and type II SMA. The prognosis and clinical course of SMA are 
highly variable, and they are more of a continuous spectrum with the age of death from 
infancy to normal life expectancy. 
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